GLP-1 News & Analysis
Weekly pricing updates, FDA alerts, and expert analysis on the fast-moving GLP-1 landscape.
Does Zepbound Cause Hair Loss? What the Data Shows (2026)
Yes — about 5.7% of patients on the highest Zepbound dose report hair shedding in clinical trials, with real-world telehealth rates running 8-12%. It's almost always temporary telogen effluvium driven by rapid weight loss, not the drug itself. Here's how to prevent it, treat it, and which providers actually screen for it.
How to Get Mounjaro for $25 a Month (2026 Savings Card Guide)
Eli Lilly's Mounjaro Savings Card drops your copay to $25/month — but only for commercially insured patients with a type 2 diabetes diagnosis. Here's exactly who qualifies, how to enroll, what to do if your insurance refuses prior auth, and the legitimate paths if $25 isn't available to you.
How Long Do Zepbound Side Effects Last? (2026 Timeline by Side Effect)
Most Zepbound side effects start within 24-72 hours of an injection and resolve in 1-2 weeks at each new dose level. Nausea peaks first; fatigue and constipation linger longer. Here's the timeline by symptom — and when persistent side effects mean it's time to adjust your dose.
Is Zepbound the Same as Mounjaro? Yes — Here's What That Means for Your Cost (2026)
Same molecule (tirzepatide), same manufacturer (Eli Lilly), same dose strengths — different FDA label. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. Here's how that affects your cost, insurance coverage, and how to access the cheapest legitimate path in 2026.
Can You Stay on a Low Dose of Wegovy? Maintenance Dose Guide (2026)
Yes — and most patients who hit their goal weight should. The FDA label says 2.4 mg, but real-world clinical practice routinely uses 1.0–1.7 mg (or lower) for maintenance. Here's what works, what insurance will pay for, and which providers will actually customize your dose.
Is Zepbound Better Than Wegovy? Head-to-Head 2026 (Cost, Results, Side Effects)
For most patients, yes. Zepbound delivers ~20% mean weight loss vs Wegovy's ~14% in the head-to-head SURMOUNT-5 trial. But cost, side effects, and the new $149/month oral pills flip the answer for some patients. Here's the 2026 breakdown.
Ozempic & GLP-1 Hair Loss: What 84,000 Patients Reveal (May 2026)
A 2026 meta-analysis of 84,000 GLP-1 users found 3.4× higher hair-loss risk vs non-users. Here's why it happens, who it hits hardest, what stops it, and which providers help.
GLP-1 Microdosing: Does It Work? Cost, Providers & What the Science Says (2026)
GLP-1 microdosing — taking 0.05-0.125mg/week instead of standard 0.25-2.4mg — is trending. Here's what clinicians actually say, who offers it, and what it costs.
"Gut Reset" May Lock In GLP-1 Weight Loss After Quitting (New Study)
A new sham-controlled trial shows a minimally invasive gut procedure helped patients keep 80% of their GLP-1 weight loss after stopping tirzepatide. Here's what it means.
Quitting and Restarting Your GLP-1? What It Does to Your Muscles (2026)
Fewer than 1 in 4 patients stay on a GLP-1 after one year. Up to 40% of weight lost is muscle. Each stop-restart cycle makes it worse. Here's what the research says — and how to avoid the trap.
24 Million Americans Just Lost GLP-1 Coverage — Here's What Actually Happened
NPR reports 12 million lost Zepbound coverage and 12 million lost Wegovy coverage in the past year. CVS Caremark, BCBS Massachusetts, and Harvard Pilgrim all pulled back. Here's the full list — and what you can do right now.
Insurance Dropped Your GLP-1? 5 Cheapest Options (2026)
41 million Americans lost commercial GLP-1 coverage in 2026. CVS Caremark dropped Zepbound, BCBS restricted Wegovy. Here are the cheapest ways to keep your medication without insurance.
Your Genes May Predict How Much Weight You'll Lose on GLP-1s (New Study)
A massive 23andMe study published in Nature found genetic variants that predict GLP-1 weight loss (6-20%) and nausea risk (5-78%). Here's what it means for choosing your medication.
Hims Drops Compounded Semaglutide: What the Novo Nordisk Deal Means for You
Hims partnered with Novo Nordisk, stopped advertising compounded GLP-1s, and now offers FDA-approved Wegovy starting at $149/month. Here's what changes for patients.
Foundayo Ships Today: How to Get Eli Lilly's GLP-1 Pill for $149/Month
LillyDirect began shipping Foundayo on April 6, 2026. Here's exactly how to order, what it costs with and without insurance, and how it compares to every other GLP-1 option.
CMS Balance Model: How Medicare's New GLP-1 Pilot Works (April 2026)
CMS's new Balance Model launches July 2026 as Medicare's first value-based GLP-1 coverage pilot. Here's what Part D patients need to know about eligibility and costs.
GLP-1 Price War: Every Option Compared (April 2026)
Foundayo ships April 6 at $149/month. Novo slashed Wegovy to $249. Medicare hits $50 in July 2026. Here's what every GLP-1 option actually costs right now.
FDA Approves Foundayo: The GLP-1 Pill You Take With Food (April 2026)
Eli Lilly's oral weight loss pill got the fastest FDA approval since 2002 on April 1, 2026. Here's how Foundayo compares to oral Wegovy at $149/month.
GLP-1 Pill War: What Orforglipron Means for You (April 2026)
Eli Lilly's oral GLP-1 pill gets its FDA decision April 10. Novo Nordisk just launched Wegovy subscriptions at $249/month. Here's what's happening now.
Medicare GLP-1 Bridge Program: 5 Things to Know Before July 2026
The $50/month Medicare GLP-1 Bridge launches July 1, 2026. Here are 5 things Part D enrollees must prepare now to lock in Wegovy, Zepbound, or Foundayo.
Oral Wegovy at 3 Months: What Early Users Report: 2026 Guide
Three months after the December 2025 launch, here's what real oral semaglutide patients say about weight loss, side effects, and the fasting requirement.
FDA Warns 12 More GLP-1 Compounders (March 2026 Update)
The FDA's March 2026 enforcement wave adds 12 new compounding pharmacies to the warning list, bringing the total past 40 since late 2025. Here's who was flagged.
GLP-1 Price Check: Cheapest Programs This Month (March 2026)
We tracked pricing across 15+ GLP-1 telehealth providers in March 2026. Here's who lowered prices, who raised them, and which compounded plan is cheapest now.
Orforglipron FDA Decision April 10: What It Means (April 2026)
Eli Lilly's oral non-peptide GLP-1 orforglipron faces its FDA PDUFA date April 10, 2026. Here's how this pill could reshape the weight loss landscape.
Stay Informed
We publish new analysis every week covering FDA decisions, provider pricing changes, and clinical trial results.